{
    "nct_id": "NCT06415487",
    "official_title": "A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE2016, an Allogeneic Anti-EGFR Conjugated Gamma Delta T Cell (gdT) Therapy in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)",
    "inclusion_criteria": "* Locally advanced unresectable or metastatic solid tumors that have failed at least two lines of therapy (one of which must be targeted therapy)\n* At least one measurable lesion as defined by RECIST v1.1 criteria\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1\n* Adequate hematologic and renal, hepatic and cardiac function\n* Oxygen saturation via pulse oximeter â‰¥92% at rest on room air\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior treatment with a genetically modified cell therapy product targeting EGFR\n* History of allogeneic transplantation\n* Subjects with active CNS metastases\n* History or presence of clinically relevant Central Nervous System (CNS) disorder (e.g. epilepsy)\n* Clinically significant active infection\n* Human Immunodeficiency Virus (HIV) infection, active hepatitis B infection, or hepatitis C infection.\n* History of malignancies with the exception of certain treated malignancies with no evidence of disease.\n* Primary immunodeficiency disorder\n* Pregnant or lactating female\n* Any medical, psychological, familial, or sociological conditions that, in the opinion of the Investigator or Sponsor Medical Monitor, would impair the ability of the subject to receive study treatment or comply with study requirements, including understanding and rendering of informed consent",
    "miscellaneous_criteria": ""
}